Isohemagglutinin Titers and Clinical Significance in Blood Bank Donors: A Single-Center Cross-sectional Cohort Study


Soydemir D., Karakaş Z., Nizam M. Y., Akcay A., Ozturk G., Tanyildiz H. G.

Innovative Journal of Pediatrics, cilt.35, sa.5, 2025 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 5
  • Basım Tarihi: 2025
  • Doi Numarası: 10.5812/ijpediatr-153406
  • Dergi Adı: Innovative Journal of Pediatrics
  • Derginin Tarandığı İndeksler: Scopus
  • Anahtar Kelimeler: ABO-Incompatible Transplantation, Blood Donation, HSCT, Isohemagglutinin Titer, Sex Differences
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Isohemagglutinins directed against ABO blood group antigens play a crucial role in transfusion and transplantation. Understanding the distribution of isohemagglutinin titers in blood donors is critical, particularly in ABO-incompatible hematopoietic stem cell transplantation (HSCT). Objectives: The present study aimed to investigate the distribution of anti-A, anti-B, IgM, and IgG titers among healthy blood donors stratified by blood group, sex, and age. Methods: In this cross-sectional study, isohemagglutinin titers were measured in 1005 randomly selected donors (335 A, 335 B, and 335 O) at a single center. Titers were evaluated using the column agglutination technique, and statistical analyses were used to compare titer distributions by sex and age group. Results: The majority of donors were male (95.2%). Elevated anti-B IgM and IgG titers were significantly more common among female donors, particularly at 1:128 and 1:256 levels for IgM (P = 0.027; P = 0.012) and at the 1:1024 level for IgG (P = 0.005). The overall distribution of the ABO and Rh blood groups in this cohort was consistent with that reported in previous Turkish studies. Conclusions: Female donors demonstrated a tendency toward higher isohemagglutinin titers, although the small number of female participants limited definitive conclusions. These findings emphasize the need to screen high-titer donors, especially in the context of ABO-incompatible HSCT, and suggest that future longitudinal studies incorporating detailed immunologic histories are warranted.